Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Cervical cancer is related to infection by the human papillomavirus (HPV). Though cervical cancer has decreased in the last 40 years as a result of HPV vaccination and Pap smear screening, it is still high among ethnic minority and foreign-born women in the US. Despite the availability of HPV vaccinations to prevent HPV infection, only about a third of female college students have received a vaccination, which falls far short of the Healthy People 2020 HPV vaccination rate goal of 80%. Furthermore, HPV vaccination and Pap smear rates have been low among Asian American women, especially among Koreans in the U.S. Thus, it is vital to develop prevention strategies for this group. Reducing racial/ethnic differences in immunization rates is an important public health goal.
Storytelling can be a powerful way to raise awareness and reduce health inequalities, since it can expand the listener or viewer's understanding of a subject within their social and cultural context by presenting 'real stories' and 'own voices' in similar life settings in which health decisions are made.
This study aimed to investigate whether culturally-grounded storytelling could increase HPV vaccination uptake by providing health information about this disease and its prevention.

Who can participate?
University undergraduate or graduate female students in the Northeast region of the USA who identify themselves as Korean or Korean American, are between the ages of 18 and 26 years, who can speak or read English, and have not yet been vaccinated.

What does the study involve?
The participants were randomly allocated to one of two groups. One group watched a story-telling video of about 17 min. The other group was given written information about HPV and vaccination. Both groups completed surveys before they received the video or written information, after they had received it and 2 months afterwards.

What are the possible benefits and risks of participating?
There were no direct risks to participants. The information learned from this study could help to increase the health and quality of life of the participants.

Where is the study run from?
University of Massachusetts Boston

When is the study starting and how long is it expected to run for?
September 2016 to December 2016

Who is funding the study?
American Cancer Society (USA)

Who is the main contact?
MinJin Kim,

Trial website

Contact information



Primary contact

Dr Minjin Kim


Contact details

285 Plantation St. 7-716
United States of America
+1 720-209-5559

Additional identifiers

EudraCT number

Nil known number

Nil known

Protocol/serial number


Study information

Scientific title

Acceptability, feasibility, and preliminary effectiveness of a mobile, web-based storytelling HPV intervention to promote HPV vaccine uptakes among Korean college women


Study hypothesis

1. Women receiving the STN intervention will have greater knowledge and more positive perceptions (cognitive) and feelings (affective) toward the HPV vaccine compared to the control group at post-intervention.
2. Women receiving the STN intervention will demonstrate a higher intention to receive the HPV vaccine (conative) compared to the control group at post-intervention and at the 2-month follow-up.
3. Women receiving the STN intervention will demonstrate higher HPV vaccine uptake compared to the control group at the 2-month follow-up.

Ethics approval

Approved 12/09/2016, University of Massachusetts Boston Institutional Review Board (Office of Research and Sponsored Programs, University of Massachusetts Boston, 100 Morrissey Boulevard, Boston, MA 02125, USA; +1 617-287-5374;, ref: #2016146

Study design

Randomized controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

No participant information sheet available.


Knowledge and attitudes toward HPV vaccination


At the end of the baseline survey, participants were randomly assigned to either the experimental group (a storytelling video intervention) or comparison group (a non-narrative, written statement about HPV and HPV vaccine) by Qualtrics software until each group contained 60 participants.

The experimental group received a theory-led, evidence-based, culturally appropriate storytelling video intervention about HPV and cervical cancer prevention. The video includes three pairs of Korean American college women’s shared thoughts, memories, and ideas about HPV, HPV vaccine and cervical cancer. Additionally, a Korean American physician provides supportive material to fill in gaps not covered by the stories and provide scientific, evidence-based information on HPV, HPV vaccine, and cervical cancer. The video is about 17 minutes in length. The comparison group received written, non-narrative education materials that include a Fact Sheet about HPV infection from the CDC and a HPV vaccine information from the American Cancer Society. Surveys were conducted via an online laboratory at baseline, at post-intervention, and at 2-month follow-up after the intervention.

Intervention type



Drug names

Primary outcome measure

Initiation of HPV vaccine uptake assessed using a self-report of HPV vaccination initiation at the 2-month follow-up after the intervention.

Secondary outcome measures

1. Knowledge about HPV vaccination
2. Attitudes toward HPV vaccination
3. Intention to receive the HPV vaccine

Surveys were conducted via an online laboratory at baseline, at post-intervention, and at 2-month follow-up after the intervention.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Current university undergraduate or graduate female students
2. Identified themselves as Korean or Korean American
3. Resident in the northeast region of the U.S.
4. Aged 18-26 years
5. Able to speak or read English
6. Not yet vaccinated against HPV

Participant type


Age group




Target number of participants


Total final enrolment


Participant exclusion criteria

Does not meet inclusion criteria

Recruitment start date


Recruitment end date



Countries of recruitment

United States of America

Trial participating centre

University of Massachusetts Boston
100 Morrissey Blvd
United States of America

Sponsor information


University of Massachusetts Boston

Sponsor details

100 Morrissey Blvd
United States of America
+1 6172875000

Sponsor type




Funder type


Funder name

American Cancer Society

Alternative name(s)

The American Cancer Society, American Cancer Society, Inc., ACS, INC., ACS

Funding Body Type

private sector organisation

Funding Body Subtype

Trusts, charities, foundations (both public and private)


United States of America

Results and Publications

Publication and dissemination plan

Results have been published. Several other articles are in press as of December 2019.

IPD sharing statement
The datasets generated and/or analysed during this study will be included in the subsequent results publication.

Intention to publish date


Participant level data

To be made available at a later date

Basic results (scientific)

Publication list

2019 acceptability results in (added 23/12/2019)
2019 baseline characteristics in (added 23/12/2019)
2020 results in (added 06/02/2020)

Publication citations

Additional files

Editorial Notes

06/02/2020: Publication reference added. 23/12/2019: Trial's existence confirmed by University of Massachusetts Boston.